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Mark Ronald Green, MD, 70, an internationally renowned expert in lung cancer research and treatment, passed away on February 23, 2015 following a battle with 
plasma cell leukemia. As remembered by colleague, Dr. Rogerio Lilenbaum “Mark Green 
was the consummate researcher – passionate, inquisitive, analytical, and unrelenting in 
the pursuit of excellence. Never one to compromise on the fundamentals, his contribu-
tions transformed the treatment of lung cancer and directly impacted patients’ lives. Mark 
inspired an entire generation of clinical researchers and his premature departure leaves a 
vacuum in the hearts of everyone he has touched. He will be remembered as one of the 
greats - a true mentor and a mensch.”
Dr. Green was born January 13, 1945 in Norwalk, Connecticut, the son of 
Dr. H. Howard Green and Irene Wouk Green. He received his BA (magna cum laude) and MD 
from Harvard University. He completed his residency training at Beth Israel Hospital and at 
the National Cancer Institute, followed by oncology fellowship training at Stanford University.
In 1976, Dr. Green joined the faculty at the University of California, San Diego 
(UCSD) where he remained for 14 years during which time he held many leadership roles 
including Head of the Division of Hematology/Oncology and Director of the UCSD Cancer 
Center, which he successfully led to its first five-year core grant. While at UCSD, he also 
held the Edwin and Evelyn Tasch Professorship in Cancer Research, which was established 
in his honor.
In 1996, Dr. Green was appointed as the Mary M. Gilbreth Chair of Clinical Oncology 
and as Director of the Hollings Cancer Center at the Medical University of South Carolina 
(MUSC) serving in these posts through 2000. He retired from the full-time faculty as 
a Professor Emeritus in 2004, took on the role as Medical Director for the Network for 
Medical Communication and Research and as a Clinical Professor of Medicine at MUSC. 
Recently Dr. Green served as chief medical officer of Xcenda, a position he held since 2007.
Dr. Green was a member of the American Board of Internal Medicine subspecialty 
Board of Medical Oncology from 1989 to 1999 and served as the subspecialty board chair 
from 1995 to 1999. He is best known for his engaged leadership and intellectual contri-
butions in the Alliance in Clinical Trials for Oncology (formerly CALGB). He was the 
longest-serving Chair of the Respiratory Committee of the CALGB, a position he held 
for over 20 years, and also served as Vice-Chairman of CALGB from 1995–2007, while 
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Dr. Richard Schilsky was Chairman. During his tenure 
as Chair of the Respiratory Committee, he oversaw the 
development of new and innovative treatments used in 30 
member universities and hundreds of hospitals and com-
munity practices and affirmed mentoring as major func-
tion of a national Cooperative Group. In the words of 
Dr. Schilsky, “Few people have impacted cancer clinical 
research in the last quarter century as much as Mark Green. 
His expertise in lung cancer and clinical trial design led to the 
successful completion of seminal studies combining radiation 
and chemotherapy that forever changed the management of 
patients with early stage lung cancer. He was deeply devoted 
to the work of the Cancer and Leukemia Group B serving for 
20 years as chair of the Respiratory Committee, and as Group 
Vice-Chair and chair of the Data and Safety Monitoring Board. 
He will be greatly missed by all who knew him.”
Dr. Green is recognized for his early investigations of 
induction chemotherapy and treatment of lung cancer as a sys-
temic disease. These investigations led to the identification of 
induction chemotherapy followed by radiation as superior to 
radiotherapy alone for patients with locoregionally advanced 
unresectable non-small cell lung cancer. Under his leadership 
the CALGB also investigated the role of adjuvant chemother-
apy for stage 1B non-small cell lung cancer, the timing of con-
current radiotherapy for limited stage small cell lung cancer 
and the role of new drugs, including taxanes, gemcitabine, and 
topotecan. Furthermore,a lung cancer tissue bank was estab-
lished to facilitate translational research. Dr. Green has more 
than 300 scientific publications to his credit and co-authored 
The Comprehensive Textbook of Thoracic Oncology.
Dr. Green was an engaged mentor of several genera-
tions of fellows and young faculty both within and outside the 
CALGB and was one of the most highly respected oncologists 
in the United States. According to Dr. Schilsky, “His greatest 
legacy, however, lies with the generations of young clinical 
investigators he mentored, many of whom have emerged as 
national leaders in cancer research. Mark’s expansive knowl-
edge of clinical oncology, keen insights, wise counsel, good 
humor and enormous generosity with his time and talent helped 
his trainees flourish and his colleagues thrive.” He was repeat-
edly honored as one of the “Best Cancer Specialists in the U.S.” 
Dr. Green served as a mentor for several investigators who are 
active in lung cancer research today. Colleague Dr. Ramaswamy 
Govindan recalls Dr. Green as “a truly a great role model for me. 
I am truly inspired by his encyclopedic knowledge, sharp wit, 
vision, passion for excellence and kindness toward others. 
The oncology community has lost an invaluable leader.” To 
honor his contributions to Hollings Cancer Center at MUSC 
and the field of thoracic oncology, the Mark R. Green, MD, 
Distinguished Endowed Visiting Professorship in Thoracic 
Oncology was established in 2011. It is held annually at 
Hollings Cancer Center and provides for an educational event 
advancing thoracic oncology
In addition to his wife, he is survived by his two daugh-
ters, Dr. Rebecca Heinowitz of Boiceville, NY, and Hillary 
G. Mahon (Christopher) of Charleston, SC; grandson, Adam 
Newman Mahon; and two brothers, Dr. Neil Green (Lesley), 
and Dr. Alan Green (Frances). The family has suggested that 
donations may be directed toward the Rabbinic Endowment 
Fund of Kahal Kadosh Beth Elohim or the Dr. Mark R. 
Green Visiting Professorship in Thoracic Oncology at MUSC 
Foundation.
Dr. Green was a great contributor to the lung cancer 
community for many years. With his sharp analytic mind he 
insisted on formulating questions precisely and to make sure 
that answers would be relevant for patient care. He will be 
greatly missed and remembered for his outstanding contribu-
tions to thoracic oncology.
